PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Therasis (New York, NY) a development-stage computational systems biology cancer HTS drug discovery platform, closed a $12M Series A financing. Participants include Tilocor Life Science.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

On-Q-lty (Waltham, MA) a development stage molecular diagnostics company incorporating microfluidics and biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors, closed a $5M Series A financing, bringing the total round to $26M. Participants include Atlas Venture, Mohr Davidow Ventures, Bessemer Venture Partners, Physic Ventures and Northgate Capital.
Note: [...]

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

MobileMD (Warminster, PA) a commercial-stage electronic medical records information exchange and clinical data repository platform, closed a $4.7M Series A financing. Participants include Health Enterprise Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Ligon Discovery (Cambridge, MA) a development-stage HTS drug-discovery platform employing Small Molecule Microarray technology, closed a $1M seed financing. Participants include incTank Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

BioVex (Woburn, MA) a clinical-stage biologics company focused on metastatic melanoma, head and neck, pancreatic and colo-rectal cancer, closed a $30M Series F bringing the entire round to $70M. Participants have included Morningside Venture, Ventech, MVM Life Science Partners, Sectoral Asset Management, Ysios Capital Partners, Forbion Capital Partners, Credit Agricole Private Equity, Harris & Harris [...]

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]